ABEO
Abeona Therapeutics Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-09-2018 | 08-09-2018 | 05-11-2018 | 03-16-2018 | 11-15-2017 | 08-15-2017 | 05-15-2017 | |
|---|---|---|---|---|---|---|---|
| Actual EPS | -0.34 | -0.25 | -0.18 | -0.19 | -0.13 | -0.21 | -0.13 |
| Consensus EPS | -0.23 | -0.16 | -0.19 | -0.13 | -0.18 | -0.13 | -0.13 |
| Estimated EPS | -0.23 | -0.16 | -0.19 | -0.13 | -0.18 | -0.13 | -0.13 |
| Number of Estimates | 4 | 5 | 3 | 3 | 3 | 2 | 2 |
| EPS Surprise | -$0.11 | -$0.09 | $0.01 | -$0.06 | $0.05 | -$0.08 |
Stats
Summary
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.
Market Cap: 760 Million
Primary Exchange: NASDAQ Capital Market
Website: http://www.abeonatherapeutics.com
Shares Outstanding: 46.8 Million
Float: 44.8 Million
Dividend: 0.0 (0.0%)
Beta: 2.318361
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 8.18 Million
Ethical Flags
Longest drawdown: 551 trading days
From: 2015-05-11 To: 2017-07-18
Lowest Point:
Homology Medicines up 4%
via: SeekingAlpha at 2018-12-10 13:08:53:000
Thinly traded gene therapy developer Homology Medicines ( FIXX +3.6% ) is up on below-average volume. Shares have rallied over 42% since touching $18.20 on November 21. More news on: Homology Medicines, MeiraGTx Holdings plc, Genprex, Inc, Healthcare stocks news, Stocks on th… read more...
Homology Medicines up 4%
via: SeekingAlpha at 2018-12-10 13:08:53:000
Thinly traded gene therapy developer Homology Medicines ( FIXX +3.6% ) is up on below-average volume. Shares have rallied over 42% since touching $18.20 on November 21. More news on: Homology Medicines, MeiraGTx Holdings plc, Genprex, Inc, Healthcare stocks news, Stocks on th… read more...
Abeona to launch pivotal study of EB-101 in RDEB in mid-2019, new CF program launched; shares up 6%
via: SeekingAlpha at 2018-12-06 15:39:23:000
Abeona Therapeutics ( ABEO +5.9% ) is up on average volume following its pipeline update during its R&D Day. Highlights: More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona to launch pivotal study of EB-101 in RDEB in mid-2019, new CF program launched; shares up 6%
via: SeekingAlpha at 2018-12-06 15:39:23:000
Abeona Therapeutics ( ABEO +5.9% ) is up on average volume following its pipeline update during its R&D Day. Highlights: More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona to launch pivotal study of EB-101 in RDEB in mid-2019, new CF program launched; shares up 6%
via: SeekingAlpha at 2018-12-06 15:39:23:000
Abeona Therapeutics ( ABEO +5.9% ) is up on average volume following its pipeline update during its R&D Day. Highlights: More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2018 Update
via: SeekingAlpha at 2018-11-26 10:05:28:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 11/14/2018. Please visit our Tracking Ole Andreas Halvorsen… read more...
Therapy For The Butterfly Child: Krystal Biotech Vs. Abeona Therapeutics
via: SeekingAlpha at 2018-11-20 09:27:30:000
By: J. Huang, C. Hsu, and V. Bartlett of Tuesday Capital, LLC Tuesday Capitals Thesis Krystal Biotech ( KRYS ) is a promising company tackling monogenic dermatologic orphan diseases with its STAR-D gene therapy platform. Recently released positive early clinical data of lead ca… read more...
Therapy For The Butterfly Child: Krystal Biotech Vs. Abeona Therapeutics
via: SeekingAlpha at 2018-11-20 09:27:30:000
By: J. Huang, C. Hsu, and V. Bartlett of Tuesday Capital, LLC Tuesday Capitals Thesis Krystal Biotech ( KRYS ) is a promising company tackling monogenic dermatologic orphan diseases with its STAR-D gene therapy platform. Recently released positive early clinical data of lead ca… read more...
Therapy For The Butterfly Child: Krystal Biotech Vs. Abeona Therapeutics
via: SeekingAlpha at 2018-11-20 09:27:30:000
By: J. Huang, C. Hsu, and V. Bartlett of Tuesday Capital, LLC Tuesday Capitals Thesis Krystal Biotech ( KRYS ) is a promising company tackling monogenic dermatologic orphan diseases with its STAR-D gene therapy platform. Recently released positive early clinical data of lead ca… read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-12 14:17:07:000
Abeona Therapeutics Inc. (ABEO) Q3 2018 Results Earnings Conference Call November 12, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Analysts Liav Abraham - Citi Maury Raycroft - Jeffries Difei… read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-12 14:17:07:000
Abeona Therapeutics Inc. (ABEO) Q3 2018 Results Earnings Conference Call November 12, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Analysts Liav Abraham - Citi Maury Raycroft - Jeffries Difei… read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-12 14:17:07:000
Abeona Therapeutics Inc. (ABEO) Q3 2018 Results Earnings Conference Call November 12, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Analysts Liav Abraham - Citi Maury Raycroft - Jeffries Difei… read more...
Abeona Therapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-11-09 16:25:58:000
Abeona Therapeutics (NASDAQ: ABEO ): Q3 GAAP EPS of -$0.34 misses by $0.08 . Revenue of $1.7M (+672.7% Y/Y) beats by $1.31M . Press Release More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...
Abeona Therapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-11-09 16:25:58:000
Abeona Therapeutics (NASDAQ: ABEO ): Q3 GAAP EPS of -$0.34 misses by $0.08 . Revenue of $1.7M (+672.7% Y/Y) beats by $1.31M . Press Release More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...
Abeona Therapeutics misses by $0.08, beats on revenue
via: SeekingAlpha at 2018-11-09 16:25:58:000
Abeona Therapeutics (NASDAQ: ABEO ): Q3 GAAP EPS of -$0.34 misses by $0.08 . Revenue of $1.7M (+672.7% Y/Y) beats by $1.31M . Press Release More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...
Abeona in-licenses REGENXBIO's NAV AAV9 vector for up to $580M
via: SeekingAlpha at 2018-11-05 11:23:38:000
Abeona Therapeutics ( ABEO +1.2% ) inks an agreement with REGENXBIO ( RGNX -5.6% ) for exclusive global rights to its NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known a… read more...
Abeona in-licenses REGENXBIO's NAV AAV9 vector for up to $580M
via: SeekingAlpha at 2018-11-05 11:23:38:000
Abeona Therapeutics ( ABEO +1.2% ) inks an agreement with REGENXBIO ( RGNX -5.6% ) for exclusive global rights to its NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known a… read more...
Abeona in-licenses REGENXBIO's NAV AAV9 vector for up to $580M
via: SeekingAlpha at 2018-11-05 11:23:38:000
Abeona Therapeutics ( ABEO +1.2% ) inks an agreement with REGENXBIO ( RGNX -5.6% ) for exclusive global rights to its NAV AAV9 vector for the treatment of four diseases: Sanfilippo syndrome type A (MPS IIIA), Sanfilippo syndrome type B (MPS IIIB), Infantile Batten Disease, also known a… read more...
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
via: PR Newswire at 2018-11-05 07:00:00:000
ROCKVILLE, Md. , Nov. 5, 2018 /PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Abeona Therapeut… read more...
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
via: PR Newswire at 2018-11-05 07:00:00:000
ROCKVILLE, Md. , Nov. 5, 2018 /PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Abeona Therapeut… read more...
REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
via: PR Newswire at 2018-11-05 07:00:00:000
ROCKVILLE, Md. , Nov. 5, 2018 /PRNewswire/ --REGENXBIO Inc.(Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Abeona Therapeut… read more...
Abeona Therapeutics: A Potential Leader In Gene Therapy
via: SeekingAlpha at 2018-11-01 11:11:35:000
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in… read more...
Abeona Therapeutics: A Potential Leader In Gene Therapy
via: SeekingAlpha at 2018-11-01 11:11:35:000
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in… read more...
Abeona Therapeutics: A Potential Leader In Gene Therapy
via: SeekingAlpha at 2018-11-01 11:11:35:000
Company overview Abeona Therapeutics (ABEO) is a clinical stage biopharmaceutical company focused on gene and cell therapy for rare genetic disease. This company has a long history starting from Access Pharmaceuticals established in 1974. It evolved with several mergers and acquisitions in… read more...
Abeona Therapeutics announces two new appointments
via: SeekingAlpha at 2018-10-18 09:18:29:000
Abeona Therapeutics (NASDAQ: ABEO ) appoints of Joo Siffert, M.D. as Head of Research and Development and Chief Medical Officer (CMO). As a result, former CMOJuan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. More news on: Abeona Therapeutics Inc… read more...
Abeona Therapeutics announces two new appointments
via: SeekingAlpha at 2018-10-18 09:18:29:000
Abeona Therapeutics (NASDAQ: ABEO ) appoints of Joo Siffert, M.D. as Head of Research and Development and Chief Medical Officer (CMO). As a result, former CMOJuan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. More news on: Abeona Therapeutics Inc… read more...
Abeona Therapeutics announces two new appointments
via: SeekingAlpha at 2018-10-18 09:18:29:000
Abeona Therapeutics (NASDAQ: ABEO ) appoints of Joo Siffert, M.D. as Head of Research and Development and Chief Medical Officer (CMO). As a result, former CMOJuan Ruiz, M.D., Ph.D. will assume the role of Head of European Medical Affairs. More news on: Abeona Therapeutics Inc… read more...
Sarepta in-licenses gene therapy for Sanfilippo A from Lysogene
via: SeekingAlpha at 2018-10-15 08:31:17:000
Sarepta Therapeutics (NASDAQ: SRPT ) inks an agreement with French biotech Lysogene for exclusive ex-Europe rights to gene therapy LYS-SAF302 for the potential treatment of mucopolysaccharidosis type IIIA ( MPS IIIA ), also known as Sanfilippo syndrome type A, a rare progressive disorder a… read more...
Sarepta in-licenses gene therapy for Sanfilippo A from Lysogene
via: SeekingAlpha at 2018-10-15 08:31:17:000
Sarepta Therapeutics (NASDAQ: SRPT ) inks an agreement with French biotech Lysogene for exclusive ex-Europe rights to gene therapy LYS-SAF302 for the potential treatment of mucopolysaccharidosis type IIIA ( MPS IIIA ), also known as Sanfilippo syndrome type A, a rare progressive disorder a… read more...
Sarepta in-licenses gene therapy for Sanfilippo A from Lysogene
via: SeekingAlpha at 2018-10-15 08:31:17:000
Sarepta Therapeutics (NASDAQ: SRPT ) inks an agreement with French biotech Lysogene for exclusive ex-Europe rights to gene therapy LYS-SAF302 for the potential treatment of mucopolysaccharidosis type IIIA ( MPS IIIA ), also known as Sanfilippo syndrome type A, a rare progressive disorder a… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-12 08:05:48:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Buy rating and $17 (70% upside) price target at Mizuho Securities. More news on: Abeona Therapeutics Inc., Sarepta Therapeutics, Inc., Alder Biopharmaceuticals Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Abeona on go with gene therapy study in MPS IIIB in Spain; shares up 1% premarket
via: SeekingAlpha at 2018-09-12 09:17:16:000
Abeona Therapeutics (NASDAQ: ABEO ) is up 1% premarket on light volume in response to its announcement that authorities in Spain have signed off on the start of a Phase 1/2 clinical trial evaluating gene therapy ABO-101 in patients with MPS IIIB or Sanfilippo syndrome type B ,… read more...
Abeona on go with gene therapy study in MPS IIIB in Spain; shares up 1% premarket
via: SeekingAlpha at 2018-09-12 09:17:16:000
Abeona Therapeutics (NASDAQ: ABEO ) is up 1% premarket on light volume in response to its announcement that authorities in Spain have signed off on the start of a Phase 1/2 clinical trial evaluating gene therapy ABO-101 in patients with MPS IIIB or Sanfilippo syndrome type B ,… read more...
Abeona on go with gene therapy study in MPS IIIB in Spain; shares up 1% premarket
via: SeekingAlpha at 2018-09-12 09:17:16:000
Abeona Therapeutics (NASDAQ: ABEO ) is up 1% premarket on light volume in response to its announcement that authorities in Spain have signed off on the start of a Phase 1/2 clinical trial evaluating gene therapy ABO-101 in patients with MPS IIIB or Sanfilippo syndrome type B ,… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update
via: SeekingAlpha at 2018-09-07 07:32:17:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Ole Andreas Halvorsen's Viking Global… read more...
Gene therapy players under pressure
via: SeekingAlpha at 2018-09-05 10:58:30:000
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...
Gene therapy players under pressure
via: SeekingAlpha at 2018-09-05 10:58:30:000
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks … read more...
Ultragenyx's Mepsevii OK'd in Europe for MPS VII
via: SeekingAlpha at 2018-08-27 16:12:34:000
As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII) of Sly syndrome, a rare inherited lysosomal storage disorder. More news on: REGENXBIO, Sangamo Therapeutics,… read more...
Ultragenyx's Mepsevii OK'd in Europe for MPS VII
via: SeekingAlpha at 2018-08-27 16:12:34:000
As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII) of Sly syndrome, a rare inherited lysosomal storage disorder. More news on: REGENXBIO, Sangamo Therapeutics,… read more...
Ultragenyx's Mepsevii OK'd in Europe for MPS VII
via: SeekingAlpha at 2018-08-27 16:12:34:000
As expected, the European Commission approves Ultragenyx's Mepsevii (vestronidase alfa) for the treatment of non-neurological manifestations of mucopolysaccharidosis VII (MPS VII) of Sly syndrome, a rare inherited lysosomal storage disorder. More news on: REGENXBIO, Sangamo Therapeutics,… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
FDA and NIH to loosen oversight of gene therapy development
via: SeekingAlpha at 2018-08-16 09:47:09:000
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study… read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-10 16:15:09:000
Abeona Therapeutics Inc. (ABEO) Q2 2018 Earnings Conference Call August 10, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Juan Ruiz - Chief Medical Officer Analysts Liav Abraham - Citi Justin … read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-10 16:15:09:000
Abeona Therapeutics Inc. (ABEO) Q2 2018 Earnings Conference Call August 10, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Juan Ruiz - Chief Medical Officer Analysts Liav Abraham - Citi Justin … read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-10 16:15:09:000
Abeona Therapeutics Inc. (ABEO) Q2 2018 Earnings Conference Call August 10, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Juan Ruiz - Chief Medical Officer Analysts Liav Abraham - Citi Justin … read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-10 16:15:09:000
Abeona Therapeutics Inc. (ABEO) Q2 2018 Earnings Conference Call August 10, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Juan Ruiz - Chief Medical Officer Analysts Liav Abraham - Citi Justin … read more...
Abeona Therapeutics Inc. (ABEO) CEO Carsten Thiel on Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-10 16:15:09:000
Abeona Therapeutics Inc. (ABEO) Q2 2018 Earnings Conference Call August 10, 2018, 10:00 AM ET Executives Christine Silverstein - SVP, Finance and IR Carsten Thiel - CEO Tim Miller - President and CSO Juan Ruiz - Chief Medical Officer Analysts Liav Abraham - Citi Justin … read more...
Abeona Therapeutics misses by $0.06, misses on revenue
via: SeekingAlpha at 2018-08-09 16:58:50:000
Abeona Therapeutics (NASDAQ: ABEO ): Q2 EPS of -$0.25 misses by $0.06 . More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Abeona Therapeutics: The Approval Pathway
via: SeekingAlpha at 2018-08-02 13:37:40:000
Editor's note: Seeking Alpha is proud to welcome Osmium Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Abeona T… read more...
Abeona Therapeutics: The Approval Pathway
via: SeekingAlpha at 2018-08-02 13:37:40:000
Editor's note: Seeking Alpha is proud to welcome Osmium Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Abeona T… read more...
Abeona Therapeutics: The Approval Pathway
via: SeekingAlpha at 2018-08-02 13:37:40:000
Editor's note: Seeking Alpha is proud to welcome Osmium Research as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Abeona T… read more...
RegeneRx announces global development deal for RGN-137; shares up 5%
via: SeekingAlpha at 2018-08-02 10:13:33:000
RegeneRx Biopharmaceuticals ( OTCQB:RGRX +5% ) announces that licensee GtreeBNT has formed a joint venture, Lenus Therapeutics, with YuYang DNA to develop RGN-137 on a global basis for the treatment of epidermolysis bullosa (EB), a rare inherited skin disorder characterized by blisters a… read more...
RegeneRx announces global development deal for RGN-137; shares up 5%
via: SeekingAlpha at 2018-08-02 10:13:33:000
RegeneRx Biopharmaceuticals ( OTCQB:RGRX +5% ) announces that licensee GtreeBNT has formed a joint venture, Lenus Therapeutics, with YuYang DNA to develop RGN-137 on a global basis for the treatment of epidermolysis bullosa (EB), a rare inherited skin disorder characterized by blisters a… read more...
RegeneRx announces global development deal for RGN-137; shares up 5%
via: SeekingAlpha at 2018-08-02 10:13:33:000
RegeneRx Biopharmaceuticals ( OTCQB:RGRX +5% ) announces that licensee GtreeBNT has formed a joint venture, Lenus Therapeutics, with YuYang DNA to develop RGN-137 on a global basis for the treatment of epidermolysis bullosa (EB), a rare inherited skin disorder characterized by blisters a… read more...
European Court makes restrictive ruling on genome editing
via: SeekingAlpha at 2018-07-30 08:05:54:000
The European Union's Court of Justice has ruled that genetically edited organisms (via a process called mutagenesis) will now be subject to EU GMO law, previously restricted to organisms derived through transgenesis (insertion of DNA from one species into another). More news on: Health C… read more...
European Court makes restrictive ruling on genome editing
via: SeekingAlpha at 2018-07-30 08:05:54:000
The European Union's Court of Justice has ruled that genetically edited organisms (via a process called mutagenesis) will now be subject to EU GMO law, previously restricted to organisms derived through transgenesis (insertion of DNA from one species into another). More news on: Health C… read more...
European Court makes restrictive ruling on genome editing
via: SeekingAlpha at 2018-07-30 08:05:54:000
The European Union's Court of Justice has ruled that genetically edited organisms (via a process called mutagenesis) will now be subject to EU GMO law, previously restricted to organisms derived through transgenesis (insertion of DNA from one species into another). More news on: Health C… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Playing The Expectations Game In Biotech
via: SeekingAlpha at 2018-07-17 21:11:17:000
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th… read more...
Genomic Medicine Q2 2018: Do Earnings Matter?
via: SeekingAlpha at 2018-07-10 20:17:11:000
My spreadsheets are now locked and loaded for the 2Q18 earnings season which begs the question: How much do earnings and estimates really matter for this group? Most of these companies are precommercial or even preclinical. Yet in a few weeks earnings will roll out with traditional media procl… read more...
Genomic Medicine Q2 2018: Do Earnings Matter?
via: SeekingAlpha at 2018-07-10 20:17:11:000
My spreadsheets are now locked and loaded for the 2Q18 earnings season which begs the question: How much do earnings and estimates really matter for this group? Most of these companies are precommercial or even preclinical. Yet in a few weeks earnings will roll out with traditional media procl… read more...
Genomic Medicine Q2 2018: Do Earnings Matter?
via: SeekingAlpha at 2018-07-10 20:17:11:000
My spreadsheets are now locked and loaded for the 2Q18 earnings season which begs the question: How much do earnings and estimates really matter for this group? Most of these companies are precommercial or even preclinical. Yet in a few weeks earnings will roll out with traditional media procl… read more...
B. Riley starts Abeona Therapeutics at 61% upside
via: SeekingAlpha at 2018-06-27 07:41:10:000
B. Riley initiates Abeona Therapeutics (NASDAQ: ABEO ) at Buy with a $26 price target, a 61% upside to yesterdays close. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
B. Riley starts Abeona Therapeutics at 61% upside
via: SeekingAlpha at 2018-06-27 07:41:10:000
B. Riley initiates Abeona Therapeutics (NASDAQ: ABEO ) at Buy with a $26 price target, a 61% upside to yesterdays close. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
B. Riley starts Abeona Therapeutics at 61% upside
via: SeekingAlpha at 2018-06-27 07:41:10:000
B. Riley initiates Abeona Therapeutics (NASDAQ: ABEO ) at Buy with a $26 price target, a 61% upside to yesterdays close. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Genomic Medicine: Is The Platform The FDA Product?
via: SeekingAlpha at 2018-06-25 12:24:52:000
Credit: Irvine/NIST The FDA is expected to release new guidelines in July which are part of an effort to modernize regulations related to cell and gene therapy. The key to these revisions may be tied to their belief that the use of novel platforms for gene therapy flips the risk profil… read more...
Genomic Medicine: Is The Platform The FDA Product?
via: SeekingAlpha at 2018-06-25 12:24:52:000
Credit: Irvine/NIST The FDA is expected to release new guidelines in July which are part of an effort to modernize regulations related to cell and gene therapy. The key to these revisions may be tied to their belief that the use of novel platforms for gene therapy flips the risk profil… read more...
Gene therapy players in the green
via: SeekingAlpha at 2018-06-20 14:27:32:000
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...
Gene therapy players in the green
via: SeekingAlpha at 2018-06-20 14:27:32:000
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...
Gene therapy players in the green
via: SeekingAlpha at 2018-06-20 14:27:32:000
Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta's ( SRPT +7.1% ) bullish news yesterday. More news on: Sarepta Therapeutics, Inc., Solid Biosciences, Inc., Fibrocell Science, Inc., Healthcare stocks news, Stocks on the move, , Read mo… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. - ABEO
via: Business Wire at 2018-06-18 16:21:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
Newman Ferrara LLP Announces Corporate Governance Investigation of Abeona Therapeutics Inc. - ABEO
via: Business Wire at 2018-06-18 16:21:00:000
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of stockholders of Abeona Therapeutics Inc. (Abeona or the Company) (NASDAQ: ABEO) into potential breaches of fiduciary duty by the Companys Board of Directors (t… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
CRISPR/Cas9 gene editors weigh on gene therapy stocks
via: SeekingAlpha at 2018-06-11 14:05:45:000
Most gene therapy stocks are in the red, led by the CRISPR/Cas9 players after two studies were published about the potential cancer risk related to edited cells. More news on: Fibrocell Science, Inc., Rocket Pharmaceuticals, Inc., Abeona Therapeutics Inc., Healthcare stocks news, Stocks on… read more...
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech
via: SeekingAlpha at 2018-06-07 16:03:56:000
Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech
via: SeekingAlpha at 2018-06-07 16:03:56:000
Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech
via: SeekingAlpha at 2018-06-07 16:03:56:000
Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
Midday Gainers / Losers (06/05/2018)
via: SeekingAlpha at 2018-06-05 12:35:14:000
Gainers: CODX +41% . NDRA +28% . SDT +32% . SNES +25% . CLDC +19% . ABEO +15% . NX +16% . ANFI +15% . ACIU +15% . SMAR +15% . More news on: Co-Diagnostics, Endra Life Sciences Inc, SandRidge Mississippian Trust I, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/05/2018)
via: SeekingAlpha at 2018-06-05 12:35:14:000
Gainers: CODX +41% . NDRA +28% . SDT +32% . SNES +25% . CLDC +19% . ABEO +15% . NX +16% . ANFI +15% . ACIU +15% . SMAR +15% . More news on: Co-Diagnostics, Endra Life Sciences Inc, SandRidge Mississippian Trust I, Stocks on the move, , Read more … read more...
Crispr On Hold While Sangamo Accelerates
via: SeekingAlpha at 2018-06-04 15:21:46:000
We're at a key point when it comes to cell and gene therapy. These therapies have the potential to address hundreds, if not thousands, of different rare and common diseases. For a long time, they were largely theoretical constructs. Now they're a therapeutic reality. And it's my expectation … read more...
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
via: SeekingAlpha at 2018-05-31 13:23:00:000
Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
via: SeekingAlpha at 2018-05-31 13:23:00:000
Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...
Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap
via: SeekingAlpha at 2018-05-31 13:23:00:000
Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...
Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?
via: SeekingAlpha at 2018-05-29 05:39:03:000
Take one simple idea and take it seriously. - Charlie Munger Buy the rumors and sell the news seemed to be the trend witnessed in the bioscience space lately. One such company that experienced the aforesaid phenomenon is Sesen Bio (NASDAQ: SESN ): the company posted robu… read more...
Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?
via: SeekingAlpha at 2018-05-29 05:39:03:000
Take one simple idea and take it seriously. - Charlie Munger Buy the rumors and sell the news seemed to be the trend witnessed in the bioscience space lately. One such company that experienced the aforesaid phenomenon is Sesen Bio (NASDAQ: SESN ): the company posted robu… read more...
Abeona Therapeutics: What The Latest Data For ABO-102 Foretells?
via: SeekingAlpha at 2018-05-29 05:39:03:000
Take one simple idea and take it seriously. - Charlie Munger Buy the rumors and sell the news seemed to be the trend witnessed in the bioscience space lately. One such company that experienced the aforesaid phenomenon is Sesen Bio (NASDAQ: SESN ): the company posted robu… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2018 Update
via: SeekingAlpha at 2018-05-27 06:18:24:000
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsens 13F stock portfolio on a quarterly basis. It is based on Viking Globals regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Ole Andreas Halvorsen&#… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Krystal Biotech's KB103 Fast Track'd for rare skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-05-24 10:13:31:000
The FDA designates Krystal Biotech's ( KRYS +2.5% ) lead gene therapy candidate KB103 for Fast Track review for the treatment of dystrophic epidermolysis bullosa (DEB), a rare inherited disorder characterized by fragile skin that blisters when subjected to the slightest friction. More ne… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Evelo Biosciences IPO: Undervalued, And Almost 40% Of It Is Cash
via: SeekingAlpha at 2018-05-24 09:50:21:000
In the financial accounts provided by Evelo Biosciences (EVLO) for its IPO, the total amount of cash shown by the company was $38.24 million, or $1.19 per share. However, I studied the prospectus more closely and discovered that the company sold preferred stock in February and March 2018 for $… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
Trump set to sign "right to try" bill; biotechs rally
via: SeekingAlpha at 2018-05-23 11:51:47:000
Many biotechs are in the green in early trade after the U.S. House of Representatives voted in favor of the Senate's version of "right to try" legislation yesterday. The bill, expected to be quickly signed into law by President Trump, will allow people with life-threatening illnesses to ob… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 22: Breast Cancer Disruption!
via: SeekingAlpha at 2018-05-23 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
via: SeekingAlpha at 2018-05-22 12:03:38:000
Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
via: SeekingAlpha at 2018-05-22 12:03:38:000
Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...
Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas
via: SeekingAlpha at 2018-05-22 12:03:38:000
Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Midday Gainers / Losers (05/21/2018)
via: SeekingAlpha at 2018-05-21 12:40:49:000
Gainers: ADOM +50% . ARTW +45% . ENT +35% . UAVS +31% . TGA +17% . EGY +18% . XTNT +17% . FUV +15% . MBFI +13% . TRXC +13% . More news on: ADOMANI, Inc., Art's-Way Manufacturing Co., Inc., Global Eagle Entertainment, Inc., Stocks on the move, , Read mor… read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
via: SeekingAlpha at 2018-05-21 10:00:00:000
Analysis focus: ABEO Abeona Therapeutics (ABEO) is down after publishing strongly positive data from its phase 1/2 trial of gene therapy drug candidate ABO-102 in patients with Sanfilippo syndrome type A (MPS III A). MPS III A is a rare inherited disorder characterized by the buildup of … read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
3 Things In Biotech, May 20: You Want Some Good News?
via: SeekingAlpha at 2018-05-21 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Midday Gainers / Losers (05/18/2018)
via: SeekingAlpha at 2018-05-18 12:51:54:000
Gainers: ORPN +31% . MTEX +24% . TYHT +20% . EOLS +18% . QTNT +17% . VLRX +17% . WMLP +16% . AQMS +12% . EGY +13% . SDR +13% . More news on: Bio Blast Pharma, Mannatech, Incorporated, Shineco, Inc., , Stocks on the move, Read more … read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Abeo down 12% on gene therapy data in Sanfilippo
via: SeekingAlpha at 2018-05-18 10:42:39:000
Abeona Therapeutics ( ABEO -11.5% ) is down on a 50% spike in volume following its release of updated data from a Phase 1/2 clinical trial assessing gene therapy ABO-102 in patients with Sanfilippo syndrome type A (MPS III A), a rare inherited disorder characterized by the buildup of s… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Bluebird Bio: Gene Therapy Best In Class
via: SeekingAlpha at 2018-05-16 11:31:47:000
I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals?
via: SeekingAlpha at 2018-05-15 14:48:11:000
Shares of gene therapy newcomer Rocket Pharmaceuticals ( RCKT ) have risen by over 80% year to date. The formerly private company came into existence (on the stock exchange) after a merger with floundering biotech firm Inotek Pharma in which shareholders of the former owned 81% of the combined… read more...
Abeona Therapeutics' (ABEO) CEO Carsten Thiel on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-14 15:45:47:000
Abeona Therapeutics, Inc. (ABEO) Q1 2018 Earnings Conference Call May 14, 2018 10:00 AM ET Executives Christine Silverstein Senior Vice President, Finance and Investor Relations Carsten Thiel Chief Executive Officer Tim Miller President and Chief Scient… read more...
Abeona Therapeutics' (ABEO) CEO Carsten Thiel on Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-14 15:45:47:000
Abeona Therapeutics, Inc. (ABEO) Q1 2018 Earnings Conference Call May 14, 2018 10:00 AM ET Executives Christine Silverstein Senior Vice President, Finance and Investor Relations Carsten Thiel Chief Executive Officer Tim Miller President and Chief Scient… read more...
Genomic Medicine: Catch The Gene Therapy Wave
via: SeekingAlpha at 2018-05-14 15:12:28:000
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project HGP this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for… read more...
Genomic Medicine: Catch The Gene Therapy Wave
via: SeekingAlpha at 2018-05-14 15:12:28:000
Genomic medicine is the future of healthcare. Spawned by the Human Genome Project HGP this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for… read more...
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
via: SeekingAlpha at 2018-05-14 11:37:23:000
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...
JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions
via: SeekingAlpha at 2018-05-14 11:37:23:000
Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...
Abeona Therapeutics beats by $0.01, beats on revenue
via: SeekingAlpha at 2018-05-11 08:20:19:000
Abeona Therapeutics (NASDAQ: ABEO ): Q1 EPS of -$0.18 beats by $0.01 . More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Abeona Therapeutics beats by $0.01, beats on revenue
via: SeekingAlpha at 2018-05-11 08:20:19:000
Abeona Therapeutics (NASDAQ: ABEO ): Q1 EPS of -$0.18 beats by $0.01 . More news on: Abeona Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
via: SeekingAlpha at 2018-05-07 15:40:31:000
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space
via: SeekingAlpha at 2018-05-07 15:40:31:000
Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
via: SeekingAlpha at 2018-05-01 02:41:27:000
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond
via: SeekingAlpha at 2018-05-01 02:41:27:000
Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...
FDA on board with clinical development of Krystal Biotech's KB103 for skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-04-26 09:56:09:000
The FDA has signed off on Krystal Biotech's ( KRYS +3.3% ) IND for lead candidate KB103, a topically administered herpes simplex virus (HSV-1)-based gene therapy, for the treatment of a rare inherited skin disorder called dystrophic epidermolysis bullosa (DEB). More news on: Krystal Bi… read more...
FDA on board with clinical development of Krystal Biotech's KB103 for skin blistering disorder; shares up 3%
via: SeekingAlpha at 2018-04-26 09:56:09:000
The FDA has signed off on Krystal Biotech's ( KRYS +3.3% ) IND for lead candidate KB103, a topically administered herpes simplex virus (HSV-1)-based gene therapy, for the treatment of a rare inherited skin disorder called dystrophic epidermolysis bullosa (DEB). More news on: Krystal Bi… read more...
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
via: SeekingAlpha at 2018-04-24 08:00:00:000
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver… read more...
Your Daily Pharma Scoop: Roche's Ocrevus, Biogen Data, Biohaven Update
via: SeekingAlpha at 2018-04-24 08:00:00:000
Analysis focus: Roche Today we will discuss Roche (RHHBY), after the company announced data with its multiple sclerosis ((MS)) treatment Ocrevus from a long-term extension study. Ocrevus has seen strong uptake since its launch last year, and is expected to be a key value driver… read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Abeona rebounds from bearish report-stoked selloff, up 1%
via: SeekingAlpha at 2018-02-15 10:38:14:000
Abeona Therapeutics ( ABEO +0.9% ) is up on modestly higher volume. Shares were down over 8% before recovering in apparent response to a bearish call from MOX Reports. More news on: Abeona Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines
via: SeekingAlpha at 2018-02-13 12:46:16:000
Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines
via: SeekingAlpha at 2018-02-13 12:46:16:000
Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines
via: SeekingAlpha at 2018-02-13 12:46:16:000
Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
Abeona Therapeutics (ABEO) A Global Phase 1/2 Clinical Trial Of Systemic Gene Transfer of scAAV9.U1a.hSGSH For MPS IIIA - Slideshow
via: SeekingAlpha at 2018-02-12 12:41:15:000
The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this Read more … read more...
Abeona Therapeutics (ABEO) A Global Phase 1/2 Clinical Trial Of Systemic Gene Transfer of scAAV9.U1a.hSGSH For MPS IIIA - Slideshow
via: SeekingAlpha at 2018-02-12 12:41:15:000
The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this Read more … read more...
Abeona Therapeutics (ABEO) A Global Phase 1/2 Clinical Trial Of Systemic Gene Transfer of scAAV9.U1a.hSGSH For MPS IIIA - Slideshow
via: SeekingAlpha at 2018-02-12 12:41:15:000
The following slide deck was published by Abeona Therapeutics Inc. in conjunction with this Read more … read more...
Abeona Therapeutics: Data Update - Part 2
via: SeekingAlpha at 2018-02-12 04:11:36:000
In the still-viewable first part of my update on Abeona Therapeutics ( ABEO ), I provided readers with a recap of the bullish thesis, financial snapshot, and upcoming catalysts that could move the stock. I also took a look at preliminary data announced for the first patient dosed in the … read more...
Abeona Therapeutics: Data Update - Part 2
via: SeekingAlpha at 2018-02-12 04:11:36:000
In the still-viewable first part of my update on Abeona Therapeutics ( ABEO ), I provided readers with a recap of the bullish thesis, financial snapshot, and upcoming catalysts that could move the stock. I also took a look at preliminary data announced for the first patient dosed in the … read more...
Abeona Therapeutics: Data Update - Part 2
via: SeekingAlpha at 2018-02-12 04:11:36:000
In the still-viewable first part of my update on Abeona Therapeutics ( ABEO ), I provided readers with a recap of the bullish thesis, financial snapshot, and upcoming catalysts that could move the stock. I also took a look at preliminary data announced for the first patient dosed in the … read more...
3 Things In Biotech You Should Learn Today: February 8, 2018
via: SeekingAlpha at 2018-02-09 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
3 Things In Biotech You Should Learn Today: February 8, 2018
via: SeekingAlpha at 2018-02-09 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
3 Things In Biotech You Should Learn Today: February 8, 2018
via: SeekingAlpha at 2018-02-09 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
3 Things In Biotech You Should Learn Today: February 8, 2018
via: SeekingAlpha at 2018-02-09 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
3 Things In Biotech You Should Learn Today: February 8, 2018
via: SeekingAlpha at 2018-02-09 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
via: SeekingAlpha at 2018-02-09 07:54:39:000
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
via: SeekingAlpha at 2018-02-09 07:54:39:000
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
via: SeekingAlpha at 2018-02-09 07:54:39:000
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
via: SeekingAlpha at 2018-02-09 07:54:39:000
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React
via: SeekingAlpha at 2018-02-09 07:54:39:000
Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback
via: SeekingAlpha at 2018-02-08 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
This ROTY Contender Just Released Promising Data
via: SeekingAlpha at 2018-02-08 04:54:14:000
Shares of Abeona Therapeutics ( ABEO ) have risen by 165% since my initial write-up and are showing decent strength today after the presentation of encouraging data for drug candidate ABO-101 in MPS IIIB (Sanfilippo syndrome type B). Figure 1: ABEO daily advanced chart (Source: … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (2/7/2018)
via: SeekingAlpha at 2018-02-07 12:53:38:000
Gainers: SNAP +38% . DRYS +28% . TRNC +26% . MODN +26% . TAT +21% . BSPM +18% . WTW +17% . PERY +17% . ABEO +16% . HZN +16% . More news on: Snap Inc., DryShips Inc., tronc, Inc., Stocks on the move, , Read more … read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
Abeono's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12%
via: SeekingAlpha at 2018-02-07 11:24:25:000
Abeona Therapeutics ( ABEO +11.6% ) is up on modestly higher volume in response to its announcement of encouraging data from the first MPS IIIB (Sanfilippo syndrome type B) patient treated with gene therapy candidate ABO-101. More news on: Abeona Therapeutics Inc., Healthcare stocks ne… read more...
ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List
via: SeekingAlpha at 2018-02-06 11:42:23:000
Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List
via: SeekingAlpha at 2018-02-06 11:42:23:000
Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 76: How To Deal With Market Selloffs And Spring Cleaning For The Contenders List
via: SeekingAlpha at 2018-02-06 11:42:23:000
Welcome to the 76th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
via: SeekingAlpha at 2018-01-31 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
via: SeekingAlpha at 2018-01-31 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...
Your Daily Pharma Scoop: Abeona's EB-101 Granted RMAT Designation, Teva To Raise Debt, Pfizer Reports Results
via: SeekingAlpha at 2018-01-31 08:00:00:000
Analysis of top Seeking Alpha coverage: Abeona Today we will discuss the update from Abeona Therapeutics ( ABEO ) with regard to its lead candidate EB-101. Abeona announced on Tuesday that the FDA granted the Regenerative Medicine Advanced Therapy ((RMAT)) designation to EB-101, the Com… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
Solid Biosciences slips
via: SeekingAlpha at 2018-01-30 12:10:06:000
Today's broad market selloff notwithstanding, recent IPO Solid Biosciences ( SLDB -11.4% ) slumps on lower-than-normal volume in apparent response to the departure of noted gene therapy researcher James Wilson from its Scientific Advisory Board. More news on: Solid Biosciences, Inc., A… read more...
ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades
via: SeekingAlpha at 2018-01-30 11:51:02:000
Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades
via: SeekingAlpha at 2018-01-30 11:51:02:000
Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades
via: SeekingAlpha at 2018-01-30 11:51:02:000
Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...
Abeona's lead candidate EB-101 nabs additional accelerated review status in U.S.; shares up 6%
via: SeekingAlpha at 2018-01-29 10:23:47:000
The FDA designates Abeona Therapeutics' ( ABEO +5.8% ) lead candidate EB-101 a Regenerative Medicine Advanced Therapy (RMAT) which provides for more frequent interactions with the FDA, priority review and accelerated approval. More news on: Abeona Therapeutics Inc., Healthcare stocks n… read more...
Abeona's lead candidate EB-101 nabs additional accelerated review status in U.S.; shares up 6%
via: SeekingAlpha at 2018-01-29 10:23:47:000
The FDA designates Abeona Therapeutics' ( ABEO +5.8% ) lead candidate EB-101 a Regenerative Medicine Advanced Therapy (RMAT) which provides for more frequent interactions with the FDA, priority review and accelerated approval. More news on: Abeona Therapeutics Inc., Healthcare stocks n… read more...
Abeona's lead candidate EB-101 nabs additional accelerated review status in U.S.; shares up 6%
via: SeekingAlpha at 2018-01-29 10:23:47:000
The FDA designates Abeona Therapeutics' ( ABEO +5.8% ) lead candidate EB-101 a Regenerative Medicine Advanced Therapy (RMAT) which provides for more frequent interactions with the FDA, priority review and accelerated approval. More news on: Abeona Therapeutics Inc., Healthcare stocks n… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Biotech: The Gates Begin To Open
via: SeekingAlpha at 2018-01-26 10:55:19:000
In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Abeona Therapeutics: Continued Upside In 2018
via: SeekingAlpha at 2018-01-26 04:44:26:000
Shares of Abeona Therapeutics (ABEO) have risen by close to 150% since my initial write-up and by over 85% since my update piece in late August . Figure 1: ABEO daily advanced chart (Source: Finviz Elite ) (Disclosure: Contains affiliate link) Keys to the bullish thesis presented i… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-23 08:46:56:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-23 08:46:56:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-23 08:46:56:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-23 08:46:56:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-23 08:46:56:000
Abeona Therapeutics (NASDAQ: ABEO ) initiated with Outperform rating and $26 (75% upside) price target by RBC Capital. More news on: Abeona Therapeutics Inc., Global Blood Therapeutics, Amgen Inc., Healthcare stocks news, Read more … read more...
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
via: SeekingAlpha at 2018-01-23 06:59:09:000
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A… read more...
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
via: SeekingAlpha at 2018-01-23 06:59:09:000
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A… read more...
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
via: SeekingAlpha at 2018-01-23 06:59:09:000
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A… read more...
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
via: SeekingAlpha at 2018-01-23 06:59:09:000
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A… read more...
FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003
via: SeekingAlpha at 2018-01-23 06:59:09:000
The FDA has accepted Swedish Orphan Biovitrum AB's ( OTCPK:BIOVF ) Investigational New Drug (IND) application for SOBI003, a chemically modified human recombinant sulfamidase, for the potential treatment of mucopolysaccharidosis type IIIA (MPS IIIA), also know as Sanfilippo syndrome type A… read more...
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst
via: SeekingAlpha at 2018-01-16 17:08:28:000
Introduction Shares of Abeona Therapeutics ( ABEO ), a clinical-stage biotechnology company that develops gene therapy products for rare diseases, could reach new heights in 2018. The stock saw impressive returns in 2017, generated by advancement of their gene therapy pipeline, most notab… read more...
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst
via: SeekingAlpha at 2018-01-16 17:08:28:000
Introduction Shares of Abeona Therapeutics ( ABEO ), a clinical-stage biotechnology company that develops gene therapy products for rare diseases, could reach new heights in 2018. The stock saw impressive returns in 2017, generated by advancement of their gene therapy pipeline, most notab… read more...
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst
via: SeekingAlpha at 2018-01-16 17:08:28:000
Introduction Shares of Abeona Therapeutics ( ABEO ), a clinical-stage biotechnology company that develops gene therapy products for rare diseases, could reach new heights in 2018. The stock saw impressive returns in 2017, generated by advancement of their gene therapy pipeline, most notab… read more...
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst
via: SeekingAlpha at 2018-01-16 17:08:28:000
Introduction Shares of Abeona Therapeutics ( ABEO ), a clinical-stage biotechnology company that develops gene therapy products for rare diseases, could reach new heights in 2018. The stock saw impressive returns in 2017, generated by advancement of their gene therapy pipeline, most notab… read more...
Abeona Therapeutics: The Upcoming Neurocognitive Catalyst
via: SeekingAlpha at 2018-01-16 17:08:28:000
Introduction Shares of Abeona Therapeutics ( ABEO ), a clinical-stage biotechnology company that develops gene therapy products for rare diseases, could reach new heights in 2018. The stock saw impressive returns in 2017, generated by advancement of their gene therapy pipeline, most notab… read more...
2018 Could Be Another Solid Year For Abeona Therapeutics
via: SeekingAlpha at 2018-01-16 08:04:01:000
Abeona Therapeutics ( ABEO ) is a clinical-stage company focusing on rare genetic diseases. In 2017, ABEO registered gains of nearly 230%, driven by its advancing rare disease pipeline. The company capitalized on this performance and completed an offering in October last year, which has signif… read more...
2018 Could Be Another Solid Year For Abeona Therapeutics
via: SeekingAlpha at 2018-01-16 08:04:01:000
Abeona Therapeutics ( ABEO ) is a clinical-stage company focusing on rare genetic diseases. In 2017, ABEO registered gains of nearly 230%, driven by its advancing rare disease pipeline. The company capitalized on this performance and completed an offering in October last year, which has signif… read more...
2018 Could Be Another Solid Year For Abeona Therapeutics
via: SeekingAlpha at 2018-01-16 08:04:01:000
Abeona Therapeutics ( ABEO ) is a clinical-stage company focusing on rare genetic diseases. In 2017, ABEO registered gains of nearly 230%, driven by its advancing rare disease pipeline. The company capitalized on this performance and completed an offering in October last year, which has signif… read more...
2018 Could Be Another Solid Year For Abeona Therapeutics
via: SeekingAlpha at 2018-01-16 08:04:01:000
Abeona Therapeutics ( ABEO ) is a clinical-stage company focusing on rare genetic diseases. In 2017, ABEO registered gains of nearly 230%, driven by its advancing rare disease pipeline. The company capitalized on this performance and completed an offering in October last year, which has signif… read more...
2018 Could Be Another Solid Year For Abeona Therapeutics
via: SeekingAlpha at 2018-01-16 08:04:01:000
Abeona Therapeutics ( ABEO ) is a clinical-stage company focusing on rare genetic diseases. In 2017, ABEO registered gains of nearly 230%, driven by its advancing rare disease pipeline. The company capitalized on this performance and completed an offering in October last year, which has signif… read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
via: PR Newswire at 2018-01-02 10:35:00:000
NEW YORK , Jan. 2, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). … read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
via: PR Newswire at 2018-01-02 10:35:00:000
NEW YORK , Jan. 2, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). … read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
via: PR Newswire at 2018-01-02 10:35:00:000
NEW YORK , Jan. 2, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). … read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
via: PR Newswire at 2018-01-02 10:35:00:000
NEW YORK , Jan. 2, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). … read more...
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Abeona Therapeutics Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
via: PR Newswire at 2018-01-02 10:35:00:000
NEW YORK , Jan. 2, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Abeona Therapeutics Inc. (NASDAQ: ABEO). … read more...
Biotech Bonanza: Biotech Stocks To Keep Shining In 2018
via: SeekingAlpha at 2017-12-19 11:58:07:000
Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...
Biotech Bonanza: Biotech Stocks To Keep Shining In 2018
via: SeekingAlpha at 2017-12-19 11:58:07:000
Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...
Biotech Bonanza: Biotech Stocks To Keep Shining In 2018
via: SeekingAlpha at 2017-12-19 11:58:07:000
Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...
Biotech Bonanza: Biotech Stocks To Keep Shining In 2018
via: SeekingAlpha at 2017-12-19 11:58:07:000
Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...
Biotech Bonanza: Biotech Stocks To Keep Shining In 2018
via: SeekingAlpha at 2017-12-19 11:58:07:000
Biotechs have had a good year so far. Not a blistering rise, but nonetheless a steady rise. Of course, one expects even stronger performance on a relative basis from a higher-risk sector, particularly when the overall market continues to record all-time highs. Perhaps such out-performance is r… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|